Nanobiotechnology and Nanomedicine Companies

Altogen Biosystems develops polymer-, lipid-, and dendrimer-based transfection technology by applying expertise in molecular biology, combinatorial chemistry, and cell biology.

AMRI is a chemistry-based drug discovery, development and manufacturing company, focusing on small molecule prescription drugs.

This is a clinical-stage product-focused molecular imaging company that has assembled expertise and IP in the field of molecular brain imaging.

Biontex specializes in the field of transfection technology, the delivery of genes or DNA to eukaryotic cells.

The company develops new treatments for cancer based on a portfolio of delivery technologies including liposomes, polymers and nanotechnologies.

Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.

Chemicell develops and produces innovative bioseparation- gene transfection and detection systems based on magnetic nano- and microparticles.

Creative Biolabs focuses on developing novel antibodies or equivalents with desired specificity and affinity for research, diagnostic, or therapeutic applications.

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates.

Serving as a contract research organization, Endotherm Life Science Molecules is a provider of medicinally relevant compounds for the discovery and development of novel small molecule drugs. The product range includes focused compound libraries, building blocks and reagents for the development of biochemical assays (fluorescent and bioluminescent dyes).

EnGeneIC aims to revolutionize the treatment of cancer by targeted delivery of drugs or siRNAs using the same versatile nano-sized delivery vehicle to address the complexities found in cancer cells.

The company is a leader in life science fluidics, microfluidics, and optics, offering a three-fold advantage to customers by bringing optofluidic paths to life with strategic partnerships, breakthrough solutions, and proven expertise.

(German language site) The company is a Contract Research Organisation for the development and improvement of advanced cell culture systems for industrial drug screening applications, biomaterial testing and pharma-toxicological research.

The company has active internal drug discovery programs focused on the identification of novel small molecule drugs for oncology, inflammation, HIV and diabetes.

The company specializes in providing protein engineering to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide, protein and antibody compounds using their proprietary technology.

nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research at Keele University and the University of Florida. The patented technology uses nanoparticles and magnetic fields to facilitate the delivery of foreign DNA into living cells.

nanoTools provides monoclonal and polyclonal antibody development services and products. Besides providing individually tailored custom solutions, the company develops, manufactures and markets phosphorylation and modification - state specific monoclonal antibodies and other innovative reagents for Signal Transduction and Alzheimer research, high throughput screening (HTS) and proteomics.

Nanovex Biotechnologies SL is an innovative technology-based spin-off from the University of Oviedo founded in 2014 that provides a wide range of services and products in the nanobiotechnology field.

Nanovex Biotechnologies SL is an innovative technology-based spin-off from the University of Oviedo founded in 2014 that provides a wide range of services and products in the nanobiotechnology field.

A biotechnology company developing microfluidic technology (NanoAssemblr™) for the development and manufacture of nanomedicines.